SB-649,868

SB-649868

Clinical data
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-([(2S)-1-([5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl)-2-piperidinyl]methyl)-4-benzofurancarboxamide
PubChem CID	25195495
ChemSpider	25069706
ChEMBL	CHEMBL1272307
Chemical and physical data
Formula	C26H24FN3O3S
Molar mass	477.549 g/mol (free base)
3D model (Jmol)	Interactive image
SMILES CC1=NC(=C(S1)C2=CC=C(C=C2)F)C(=O)N3CCCC[C@H]3CNC(=O)C4=C5C=COC5=CC=C4
InChI InChI=1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1 Key:ZJXIUGNEAIHSBI-IBGZPJMESA-N

SB-649868 is a dual orexin receptor antagonist in development by GlaxoSmithKline. The drug is currently in phase II development for insomnia.

A phase I study evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects.

In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency. The subsequent study added a 60 mg dose and observed dose-dependent sleep promotion.